CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Accounts Receivables
€17.1m
CAGR 3-Years
112%
CAGR 5-Years
20%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Accounts Receivables
€2.2B
CAGR 3-Years
136%
CAGR 5-Years
158%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Accounts Receivables
€25.9m
CAGR 3-Years
-37%
CAGR 5-Years
5%
CAGR 10-Years
10%
Immatics NV
NASDAQ:IMTX
Accounts Receivables
€4.1m
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Accounts Receivables
€170m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Accounts Receivables
€28.2m
CAGR 3-Years
54%
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Accounts Receivables?
Accounts Receivables
17.1m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Accounts Receivables amounts to 17.1m EUR.

What is CureVac NV's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
20%

Over the last year, the Accounts Receivables growth was 90%. The average annual Accounts Receivables growth rates for CureVac NV have been 112% over the past three years , 20% over the past five years .

Back to Top